Citadel Advisors
AIDX

Citadel Advisors’s 20/20 Biolabs Inc AIDX Stock Holding History

Citadel Advisors’s Portfolio AIDX Stock Details AIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8K Buy
23,205
+6,978
+43% +$8.76K ﹤0.01% 13470
2026
Q1 		$30.5K Buy
+16,227
New +$68.5K ﹤0.01% 12566

Other funds holding AIDX

CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.99B AUM 23.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $412M AUM 34.27% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

Citadel Advisors's AIDX Position: Q2 2026 in Review

Citadel Advisors increased its 20/20 Biolabs Inc (AIDX) stake by 43% in Q2 2026, buying an estimated $8.76K and bringing the position to 23,205 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #13470.

Citadel Advisors first reported a position in AIDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $30.5K in Q1 2026. 15 funds tracked by Wall St. Rank hold AIDX as of Q2 2026.

  • Citadel Advisors held 23,205 shares of 20/20 Biolabs Inc worth $12.8K as of Q2 2026.
  • Citadel Advisors bought 6,978 20/20 Biolabs Inc shares in Q2 2026, an estimated $8.76K.
  • 20/20 Biolabs Inc made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13470 holding.
  • Citadel Advisors first reported a position in 20/20 Biolabs Inc in Q1 2026 and has held it in 2 quarters since.
  • Citadel Advisors's 20/20 Biolabs Inc position peaked at $30.5K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held 20/20 Biolabs Inc as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.